ARS Pharmaceuticals' Epinephrine Nasal Spray Secures Approval In Japan, Stock Up

(RTTNews) - ARS Pharmaceuticals, Inc. (SPRY), Friday announced that the Pharmaceuticals and Medical Devices Agency or PMDA has approved neffy 1 mg and 2 mg doses for the emergency treatment of allergic reactions.

The approval was secured in partnership with Japanese pharmaceutical company, Alfresa Holdings, which owns the rights to market neffy in Japan, and expects availability in the fourth quarter of 2025.

As per the partnership agreement, ARS Pharma is eligible to receive a final regulatory milestone of $2 million, and to sell neffy to Alfresa at a transfer price.

The company expects regulatory approvals for neffy in Canada with ALK, Australia and New Zealand in partnership with CSL in early 2026. Meanwhile, it anticipates the same in China in partnership with Pediatrix in the first half of 2026.

Currently, SPRY is moving up 4.53 percent, to $10.38 on the Nasdaq.